BioMed Realty Trust Prices Public Offering Of 15,000,000 Shares Of Common Stock

  BioMed Realty Trust Prices Public Offering Of 15,000,000 Shares Of Common
                                    Stock

PR Newswire

SAN DIEGO, March 27, 2013

SAN DIEGO, March 27, 2013 /PRNewswire/ --BioMed Realty Trust, Inc. (NYSE:
BMR) today announced the pricing of its public offering of 15,000,000 shares
of its common stock at $21.40 per share. The offering is expected to close on
or about April 2, 2013. The gross proceeds from the offering will be
approximately $321.0 million. BioMed Realty expects to use the net proceeds
of the offering to fund a portion of the purchase price for the recently
announced, pending acquisition of Wexford Science & Technology, LLC, to repay
a portion of the outstanding indebtedness under its unsecured line of credit
and for other general corporate and working capital purposes. The acquisition
of Wexford Science & Technology is subject to the receipt of lender, ground
lessor and other third-party consents, waivers of rights of first offer and
customary closing conditions, and there can be no assurances that the
acquisition will close on the terms described, or at all. All of the shares
are being sold by the company.

BioMed Realty has also granted the underwriters a 30-day option to purchase up
to an additional 2,250,000 shares of its common stock. Morgan Stanley & Co.
LLC, Raymond James & Associates, Inc., UBS Securities LLC, Wells Fargo
Securities, LLC and KeyBanc Capital Markets Inc. are the joint book-running
managers for the offering.

The registration statement relating to these securities has become effective
by rule of the Securities and Exchange Commission. This press release shall
not constitute an offer to sell or the solicitation of an offer to buy any of
the offered shares, nor shall there be any sale of such shares in any state or
other jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the securities laws of
such state or other jurisdiction. The offering of BioMed Realty's common
stock will be made only by means of a prospectus and a related prospectus
supplement, copies of which may be obtained by contacting Morgan Stanley & Co.
LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New
York 10014, at 1-866-718-1649 or by email at prospectus@morganstanley.com;
Raymond James & Associates, Inc., 880 Carillon Parkway, St. Petersburg,
Florida 33716, by calling toll-free at 1-800-248-8863 or by email at
prospectus@raymondjames.com; UBS Securities LLC, Attention: Prospectus
Department, 299 Park Avenue, New York, New York 10171, or toll-free at
1-888-827-7275; Wells Fargo Securities, LLC, Attention: Equity Syndicate
Department, 375 Park Avenue, New York, New York 10152, at 1-800-326-5897 or by
email at cmclientsupport@wellsfargo.com; or KeyBanc Capital Markets Inc.,
Attention: Prospectus Delivery Department, 127 Public Square, 4th Floor,
Cleveland, Ohio 44114, telephone: 1-800-859-1783.

About BioMed Realty Trust

BioMed Realty delivers optimal real estate solutions for biotechnology and
pharmaceutical companies, scientific research institutions, government
agencies and other entities involved in the life science industry. BioMed
Realty owns or has interests in properties comprising approximately 13.2
million rentable square feet. The company's properties are located
predominantly in the major U.S. life science markets of Boston, San Francisco,
Maryland, San Diego, New York/New Jersey, Pennsylvania and Seattle, which have
well-established reputations as centers for scientific research.



This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These risks
and uncertainties include, without limitation: the possibility that the
company's merger with Wexford Science & Technology may not occur on the terms
described, or at all; failure to manage effectively the company's growth and
expansion into new markets, or to complete or integrate acquisitions and
developments successfully, including the company's merger with Wexford Science
& Technology and related development projects; the company's ability to meet
projected yields on properties, including projected yields on properties to be
acquired in connection with the company's merger with Wexford Science &
Technology; general risks affecting the real estate industry (including,
without limitation, the inability to enter into or renew leases, dependence on
tenants' financial condition, and competition from other developers, owners
and operators of real estate); adverse economic or real estate developments in
the life science industry or the company's target markets; risks associated
with the availability and terms of financing, the use of debt to fund
acquisitions, developments and other investments, and the ability to refinance
indebtedness as it comes due; failure to maintain the company's investment
grade credit ratings with the ratings agencies; reductions in asset valuations
and related impairment charges; risks and uncertainties affecting property
development and construction; risks associated with downturns in foreign,
domestic and local economies, changes in interest rates and foreign currency
exchange rates, and volatility in the securities markets; ownership of
properties outside of the United States that subject the company to different
and potentially greater risks than those associated with the company's
domestic operations; risks associated with the company's investments in loans,
including borrower defaults and potential principal losses; potential
liability for uninsured losses and environmental contamination; risks
associated with the company's potential failure to qualify as a REIT under the
Internal Revenue Code of 1986, as amended, and possible adverse changes in tax
and environmental laws; and risks associated with the company's dependence on
key personnel whose continued service is not guaranteed. For a further list
and description of such risks and uncertainties, see the reports filed by the
company with the Securities and Exchange Commission, including the company's
most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The
company disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.

SOURCE BioMed Realty Trust, Inc.

Website: http://www.biomedrealty.com
Contact: Rick Howe, Senior Director, Corporate Communications, 858.207.5859,
richard.howe@biomedrealty.com
 
Press spacebar to pause and continue. Press esc to stop.